AIM Therapy for Cats with Kidney Disease

Chronic kidney disease (CKD) is one of the most common — and most heartbreaking — diagnoses in older cats. For years, treatment has focused on slowing progression and managing symptoms. A new therapy called AIM therapy may offer something different: a way to target part of the disease process itself.

In April 2026, a Tokyo-based biotechnology company formally submitted a drug application to Japan's Ministry of Agriculture, Forestry and Fisheries for FeliAIM, an AIM-based veterinary drug for feline CKD. The move followed promising clinical observations reported by NHK and a peer-reviewed study published in The Veterinary Journal.

Here's what the science actually says — and what cat parents should know now.

Cats develop CKD more often than dogs or humans. The reason wasn't well understood until a 2016 study in Scientific Reports found something unexpected in feline biology.

The study identified a protein called AIM — Apoptosis Inhibitor of Macrophage — that plays a critical role in kidney repair. During kidney injury, dead cell fragments accumulate inside the tubules (the kidney's tiny filtration channels). AIM normally "tags" this debris so the body can clear it.

The result: debris isn't cleared efficiently, recovery from acute injury is impaired, and the damage may compound over time into chronic disease. This discovery became the scientific foundation for AIM therapy.

Current CKD management remains essential. Standard care typically includes:

These interventions can meaningfully extend a cat's life and comfort. But none address the debris-clearance mechanism identified in the 2016 research.

AIM therapy aims to supplement what cats' biology appears to lack: a functional AIM signal that helps tubules clean themselves after injury. Rather than managing a damaged kidney, the goal is to help the kidney defend and repair itself more effectively.

The most significant published evidence comes from a 2026 exploratory study in The Veterinary Journal (Tezuka et al.). Researchers screened 216 cats with CKD, enrolling 35 who met specific criteria.

Among the 26 higher-risk cats with elevated uremic toxin levels (serum creatinine 2.9–5.0 mg/dL, indoxyl sulfate ≥5 µg/mL):

• 6 received mouse recombinant AIM
• 5 received feline recombinant AIM
• 15 served as untreated controls

Cats were followed for 360 days. Here are the key results:

Researchers also reported less worsening of kidney biomarkers, reduced uremic toxin accumulation, and recovery of serum sphingomyelins associated with anti-inflammatory and anti-fibrotic effects.

Separately, 9 cats with lower indoxyl sulfate concentrations had 100% survival at 360 days without any treatment — a finding the authors noted may help define which cats benefit most.

On April 24, 2026, IAM CAT (Tokyo) submitted a formal application to Japan's Ministry of Agriculture, Forestry and Fisheries for manufacturing and marketing approval of FeliAIM as a veterinary drug for feline CKD.

That step matters. It means the therapy has moved from laboratory research into formal regulatory review — a meaningful milestone.

FeliAIM is an investigational pharmaceutical drug under regulatory review. It is not a food product, a supplement, or any commercial product currently on the market. Any product referencing "AIM" in consumer marketing is not the same thing and should not be treated as equivalent.

The most important action is not to wait.

Even as exciting therapies emerge, nutrition remains one of the most powerful tools in kidney care.

Hydration support and palatable food can make a major difference for many cats.